RESULTS OF INVESTIGATION: Analysis showed that the tablets contained from 9.8 percent to 112.3 percent of the labeled amount of halazone. The National Formulary provides that halazone tablets contain not less than 90 percent of the labeled amount of halazone.

Libeled: 7-22-55, S. Dist. Calif.

CHARGE: 501 (b)—the article, while held for sale, purported to be and was represented as "Halazone Tablets," a drug the name of which is recognized in the National Formulary, an official compendium, and its strength differed from the standard set forth in such compendium.

Disposition: 8-15-55. Default—destruction.

4908. Petronet dressings. (F. D. C. No. 38218. S. No. 29-364 M.)

QUANTITY: 123 tins at Hackensack, N. J.

SHIPPED: 4-4-55, from Leicester, England, by Dalmas, Ltd.

Label in Part: (Tin) "Petronet Dressings A non-adhesive open mesh petroleum gauze dressing \* \* \* Sterilized \* \* \* Size 8 yards x 3% inches \* \* \* Made in England."

RESULTS OF INVESTIGATION: Examination showed that the article was not sterile but was contaminated with living micro-organisms.

Libeled: 6-30-55, Dist. N. J.

CHARGE: 501 (c)—the purity and quality of the article, when shipped, fell below that which it purported and was represented to possess; and 502 (a)—the label statement "Sterilized" was false and misleading.

DISPOSITION: 8-12-55. Default—destruction.

## DRUGS AND DEVICES ACTIONABLE BECAUSE OF FALSE AND MISLEADING CLAIMS

## DRUGS FOR HUMAN USE\*

4909. Paracyl tablets. (F. D. C. No. 37613. S. Nos. 3-816/7 M.)

QUANTITY: 1 drum containing 19,900 tablets, and 94 btls., 50-tablets each, at Rochester, N. Y., in possession of Pharma-Seal, Inc.

SHIPPED: 11-22-54, from Philadelphia, Pa.

RESULTS OF INVESTIGATION: The tablets were shipped in interstate commerce in bulk, and, upon receipt by the consignee, a number of the tablets were repacked into bottles.

Libeled: 1-19-55, W. Dist. N. Y.

CHARGE: 502 (a)—the labeling of the article (as repackaged), while held for sale, contained false and misleading representations that it was an adequate and effective treatment for arthritis and rheumatism.

Disposition: 3-4-55. Consent—claimed by Pharma-Seal, Inc. The article was relabeled.

4910. Rhu-Mart tablets. (F. D. C. No. 37684. S. No. 11-830 M.)

QUANTITY: 1,920 cartoned btls., each containing 60 tablets, at Newark, N. J., in possession of Rhu-Mart Drug Co.

SHIPPED: 12-1-54, from Cleveland, Ohio.

<sup>\*</sup>See also Nos. 4882, 4888, 4889, 4891, 4893, 4894, 4899, 4901, 4902, 4908,

LABEL IN PART: (Carton & btl.) "Rhu-Mart Tablets For Relief of Pains of Arthritis Rheumatism Neuritis Sciatica Lumbago Bursitis Active Ingredients Para-Aminobenzoic Acid (3 grs.) 0.2 GM. Sodium Salicylate (5 grs.) 0.3 GM. Ascorbic Acid 50. mgm. Rhu-Mart Drug Co. Newark, New Jersey."

ACCOMPANYING LABELING: A window streamer entitled "Rhu-Mart Tablets for Arthritis Rheumatism" and leaflets entitled "Rhu-Mart Tablets Rheumatism? Arthritis? Neuritis? Sciatica? Lumbago? Bursitis?"

RESULTS OF INVESTIGATION: The article was shipped in bulk from Cleveland, Ohio, and, after its receipt by the consignee, was repacked into the above-described cartons and bottles. The leaflets and window streamer were printed locally for the consignee.

Libeled: 3-1-55, Dist. N. J.

CHARGE: 502 (a)—the labeling of the article, while held for sale, contained false and misleading representations that the article was an adequate and effective treatment for rheumatism, arthritis, neuritis, sciatica, lumbago, and bursitis.

DISPOSITION: 5-24-55. Consent—claimed by Rhu-Mart Drug Co. and relabeled.

4911. Magonate tablets and Antabex tablets. (F. D. C. No. 37647. S. Nos. 3-778/9 M.)

QUANTITY: 1 drum containing 22,900 Magonate tablets and 1 btl. containing 5.000 Antabex tablets at Auburn, N. Y., in possession of Bexatol Vitamin Products, Inc.

SHIPPED: 3-23-54, from Camden, N. J., by Olmstead Laboratories, Inc.

LABEL IN PART: (Drum) "Magonate Each tablet contains Calcium Carbonate precip. 3.5 gr. Magnesium Carbonate 2.5 gr. Bismuth Subcarbonate 1.0 gr. Aromatics q. s. Dose: 2 or 3 tablets 3 or 4 times daily. \* \* \*Olmstead Laboratories Camden New Jersey"; (btl.) "Antabex Tablets \* \* \* Each tablet contains: Calcium Carbonate Precip. 3.5 gr. Magnesium Carbonate 2.5 gr. Bismuth Subcarbonate 1.0 gr. Aromatics q. s. Dose: 2 or 3 tablets 3 or 4 times daily. \* \* \* Distributors Bexatol Vitamin Products, Inc. Auburn, New York."

RESULTS OF INVESTIGATION: The tablets were shipped from Camden, N. J., in bulk, and, after their receipt by the consignee, a number of the tablets were repackaged into the above-described bottle.

LIBELED: 2-11-55, N. Dist. N. Y.

CHARGE: 502 (a)—the labeling of the tablets, when shipped and while held for sale, contained false and misleading representations that the article was effective for the treatment of peptic ulcers.

Disposition: 3-22-55. Default—delivered to a charitable institution for use as an antacid preparation.

4912. Special Formula tablets. (F. D. C. No. 37970. S. No. 18–594 M.)

QUANTITY: 23,000 tablets in 1 drum at Newburgh, N. Y.

SHIPPED: 9-5-44, from Cedar Rapids, Iowa.

Label In Part: (Drum) "Special Formula Tablets S. C. Red Each tablet contains as active ingredients: Uritone—½ Gr. Methylene Blue—½ Gr. Ext. Uva Ursi—½ Gr. Ext. Triticum—¼ Gr. Oil Juniper—Q. S. \* \* \* Bulk Shipment For Repacking. To Be Properly Labeled By Consignee."